DXCM Stock Recent News

Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster strength but suggest investors bring an "umbrella' to protect their portfolios.

ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.

ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.

On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.

DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday.

DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Steve Lichtman - Oppenheimer Issie Kirby - Redburn-Atlantic Michael Polark - Wolfe Research Patrick Wood - Morgan Stanley Sam Eiber - BTIG Mike Kratky - Leerink Operator Thank you for standing by.

DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion.

The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago.